<DOC>
	<DOCNO>NCT02456857</DOCNO>
	<brief_summary>The goal clinical research study learn receive 4 cycle experimental chemotherapy surgery help shrink size tumor breast and/or lymph node remove surgery . The safety combination also study .</brief_summary>
	<brief_title>Women 's Triple-Negative First-Line Study : Liposomal Doxorubicin , Bevacizumab Everolimus ( DAE ) Patients With Localized Triple-Negative Breast Cancer ( TNBC ) With Tumors Predicted Insensitive Standard Neoadjuvant Chemotherapy</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , 4 cycle chemotherapy surgery . Each cycle 21 day . On Day 1 cycle , receive liposomal doxorubicin vein 3 hour , bevacizumab vein 90 minute ( 4Â½ hour total ) . You also give 21-day supply everolimus take mouth time every day cycle . To reduce possibility side effect surgery , receive bevacizumab 4th cycle . Do skip dos unless study doctor tell . If throw take everolimus , NOT take another tablet day . Let study doctor know vomit . If forget take everolimus one day , take extra dos next day . Call study doctor ask advice . If side effect , study doctor may decide low study drug dose stop take drug . If happens , study doctor staff let know safe restart study drug later low dose . The study doctor discus . If study drug stop , may extra clinic visit safety test . Study Visits : On Day 1 cycle : - You physical exam . - Blood ( 2 teaspoon ) urine collect routine test . After receive 4 cycle chemotherapy , time disease appear get bad , image scan similar one screen check status disease . If disease get bad , may come study might either chemotherapy surgery . You may surgery remove disease . You give surgery consent form describe procedure risk . Length Treatment : You may receive 4 cycle chemotherapy . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . Follow-Up : About 2-3 week surgery , follow-up visit ask . The following test preform : - You physical exam . - Blood ( 2 teaspoon ) urine collect routine test . - If doctor think need , ultrasound , MRI , CT scan chest check status disease . This investigational study . Liposomal doxorubicin FDA approve commercially available treatment breast cancer . Bevacizumab everolimus FDA approve condition type cancer . However , neither bevacizumab everolimus FDA-approved triple-negative breast cancer . They currently use research purpose set triple-negative breast cancer treatment surgery . The study doctor explain study drug design work . Up 37 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age &gt; /= 18 year . 2 . ECOG performance status 0 1 . 3 . Confirmed invasive triplenegative breast cancer define ER &lt; 10 % ; PR &lt; 10 % immunohistochemistry ( IHC ) HER2 01+ ( IHC ) , 2+ ( FISH &lt; 2 , gene copy number &lt; 4 ) . 4 . Clinical radiologic primary tumor size least 1.5cm prior enrollment onto protocol 20140185 . 5 . Primary tumor sample collect NACT start ( protocol 20140185 ) 6 . Undergone molecular test integral biomarkers include immunohistochemical staining vimentin . 7 . Received least one dose anthracyclinebased NACT . Patients eligible therapy discontinue due disease progression therapy intolerance . 8 . At least 1.0 cm measurable residual disease neoadjuvant anthracyclinebased chemotherapy . 9 . Baseline MUGA echocardiogram show LVEF &gt; /=50 % least 6 week prior initiation NACT . 10 . Adequate bone marrow function show : ANC &gt; /=1.5 x 10^9/L , Platelets &gt; /=100 x 10^9/L , Hb &gt; 9 g/dL ; 11 . Adequate liver function show : Total serum bilirubin &lt; /=2.0 mg/dL , ALT AST &lt; /=2.5x ULN ( &lt; /=5x ULN patient liver metastasis ) , INR &lt; /=2 ; 12 . Adequate renal function show : Serum creatinine &lt; /=1.5x ULN ; 13 . Fasting serum cholesterol &lt; /=300 mg/dL OR &lt; /=7.75 mmol/L , AND fast triglyceride &lt; /=2.5x ULN . NOTE : In case one threshold exceed , patient include initiation appropriate lipid lowering medication ; 14 . Signed informed consent obtain prior screen procedure . 1 . Pregnant lactate woman . 2 . Presence metastatic disease . 3 . Prior therapy bevacizumab , liposomal doxorubicin , everolimus . 4 . Prior radiation therapy primary breast carcinoma axillary lymph node . 5 . Patients history another primary malignancy , exception : nonmelanoma skin cancer , carcinoma situ cervix , uterus , breast patient disease free &lt; /= 3 year . 6 . Prior cumulative dose doxorubicin great 360 mg/m2 epirubicin great 640 mg/m2 . 7 . Any serious medical illness , treat study , would limit survival le 1 month psychiatric illness would limit informed consent . 8 . Patients history serious cardiac event define : New York Heart Association Class 3 4 heart failure , history myocardial infarction , Unstable angina , CVA within 6 month protocol registration . History PR prolongation AV block . 9 . Known intolerance hypersensitivity rapamycin analog ( e.g . sirolimus , temsirolimus ) . 10 . Known impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral Everolimus ; 11 . Uncontrolled diabetes mellitus define HbA1c &gt; 8 % despite adequate therapy . Patients known history impair fast glucose diabetes mellitus ( DM ) may include , however blood glucose antidiabetic treatment must monitor closely throughout trial adjust necessary ; 12 . Patients severe and/or uncontrolled medical condition : a. serious uncontrolled cardiac arrhythmia , clinically significant cardiac disease b. active ( acute chronic ) uncontrolled severe infection , liver disease cirrhosis , decompensated liver disease , active chronic hepatitis ( i.e . quantifiable HBVDNA and/or positive HBsAg , quantifiable HCVRNA ) , c. know severely impaired lung function ( spirometry DLCO 50 % less normal O2 saturation 88 % less rest room air ) , d. active , bleeding diathesis ; e. Moderate severe hepatic impairment ( ChildPugh B C ) 13 . Chronic treatment corticosteroid immunosuppressive agent . Topical inhale corticosteroid allow ; 14 . Known history HIV seropositivity ; 15 . Patients receive live attenuate vaccine within 1 week start Everolimus study . Patient also avoid close contact others receive live attenuate vaccine . Examples live attenuate vaccine include intranasal influenza , measles , mumps , rubella , oral polio , BCG , yellow fever , varicella TY21a typhoid vaccine ; 16 . Patients history noncompliance medical regimen consider potentially unreliable able complete entire study ; 17 . Patients currently part participate clinical investigation investigational drug within 1 month prior dose ; 18 . Women childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , must use highly effective method contraception study 8 week . Highly effective contraception method include combination two list protocol . 19 . Male patient whose sexual partner ( ) WOCBP willing use adequate contraception , study 8 week end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Triple-Negative Breast Cancer</keyword>
	<keyword>TNBC</keyword>
	<keyword>Tumors insensitive standard neoadjuvant chemotherapy</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>CCI-779</keyword>
	<keyword>Torisel</keyword>
	<keyword>Liposomal Doxorubicin</keyword>
	<keyword>Doxil</keyword>
	<keyword>Doxorubicin Hydrochloride ( Liposomal )</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Anti-VEGF Monoclonal Antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
</DOC>